Presentation is loading. Please wait.

Presentation is loading. Please wait.

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

Published byHugh Greene Modified over 5 years ago

Similar presentations

Presentation on theme: "1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo"— Presentation transcript:

1 1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo
h h h 24h 1 μM Selinexor 1A 1B 0.4 μM Selinexor Selinexor (μM ) HT29 LoVo

2 Supplementary Figure 2. HT29 cells LOVO cells Radiation dose
DMSO 0.3 μM 0.5 μM 1 μM Selinexor 8h 0 Gy 1 Gy 5 Gy Radiation dose LOVO cells HT29 cells 1.5 μM *** ** Selinexor (μM) Number of colonies

3 Supplementary Figure 3. 3A Day 1 Gy / 5 Gy Selinexor 3B

4 Supplementary Figure 4. Selinexor 5 Gy ***

Download ppt "1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo"

Similar presentations

Supplementary Table 1 A. B. CI simulations display synergism (CI 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right.

Supplementary Table 1 A. B. CI simulations display synergism (CI 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right.
00.111000.1110 A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S1 0.004.01.040.01.030.10.313100.01.11.

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
E2 GSCE2 bulkG7 GSCG7 bulk Mean SF4Gy (95% CI) 0.78 (0.72, 0.83) 0.56 (0.47, 0.64) 0.65 (0.57,0.72) 0.43 (0.34,0.51) T test of meansp = 0.001p = 0.002.

E2 GSCE2 bulkG7 GSCG7 bulk Mean SF4Gy (95% CI) 0.78 (0.72, 0.83) 0.56 (0.47, 0.64) 0.65 (0.57,0.72) 0.43 (0.34,0.51) T test of meansp = 0.001p =
Supplementary Figure 2: PBX1 induces morphological and cytoskeletal changes consistent with differentiation in NB. A) Morphology of SHSY5Y cells. Cells.

Supplementary Figure 2: PBX1 induces morphological and cytoskeletal changes consistent with differentiation in NB. A) Morphology of SHSY5Y cells. Cells.
Supplementary Figure 1: Silibinin has no considerable radiosensitizer effect on radioresponsive prostate cancer 22RV1 cells. (A) Effect of IR and SB on.

Supplementary Figure 1: Silibinin has no considerable radiosensitizer effect on radioresponsive prostate cancer 22RV1 cells. (A) Effect of IR and SB on.
Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.

Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.
Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.
Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%
B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.

B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.
SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.
Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin.

Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin.
MDA-MB-468 48h MDA-MB-231 48h a MDA-MB-231 72h MDA-MB-468 MDA-MB-436 48h MDA-MB-436 72h MCF-7 48h MCF-7 72h b c ef g h MDA-MB-468 72h clomipramine.

MDA-MB h MDA-MB h a MDA-MB h MDA-MB-468 MDA-MB h MDA-MB h MCF-7 48h MCF-7 72h b c ef g h MDA-MB h clomipramine.
Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1.

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b
Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)

Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Differential Responses of Human Papillary Thyroid.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Differential Responses of Human Papillary Thyroid.
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Supplementary Figure S1 a

Supplementary Figure S1 a
Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.
B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Similar presentations

Ads by Google